var data={"title":"Orlistat: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Orlistat: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6687?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=orlistat-patient-drug-information\" class=\"drug drug_patient\">see &quot;Orlistat: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203918\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Alli [OTC];</li>\n      <li>Xenical</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203919\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Xenical</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203947\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Lipase Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203922\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Obesity management:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Xenical: 120 mg 3 times daily with each main meal containing fat (during or up to 1 hour after the meal); omit dose if meal is occasionally missed or contains no fat.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alli: OTC labeling: 60 mg 3 times daily with each main meal containing fat (maximum dose: 180 mg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment with concomitant therapy:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cyclosporine: Administer cyclosporine 3 hours after orlistat.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Levothyroxine: Administer levothyroxine and orlistat at least 4 hours apart and monitor for changes in thyroid function.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203935\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Obesity management (Xenical):</b> Children &ge;12 years and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203923\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20548142\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;margin-top:0em;display:inline\">There are no dosage adjustments provided in the  manufacturer&rsquo;s labeling (has not been studied). However, dosage adjustment unlikely due to low systemic absorption. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20548143\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the  manufacturer&rsquo;s labeling (has not been studied). However, dosage adjustment unlikely due to low systemic absorption. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203901\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Alli: 60 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xenical: 120 mg [contains fd&amp;c blue #2 (indigotine)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203888\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7286032\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer during or up to 1 hour after each main meal containing fat; separate dose by at least 2 hours from multivitamin daily supplement. Omit dose if a meal is missed or contains no fat. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203902\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Obesity management:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>OTC:</i> Weight loss in overweight adults when used along with a reduced-calorie and low-fat diet.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Rx:</i> Obesity management, including weight loss and weight maintenance, when used in conjunction with a reduced-calorie diet; to reduce the risk for weight regain after prior weight loss.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Orlistat is indicated for obese patients with an initial body mass index of &ge;30 kg/m<sup>2</sup> or &ge;27 kg/m<sup>2</sup>  in the presence of other risk factors (eg, hypertension, diabetes, dyslipidemia).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2702460\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Xenical may be confused with Xeloda</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203895\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">The frequency of most adverse reactions (especially gastrointestinal effects) decreases over time. Frequency not always defined. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Pedal edema (&le;3%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Headache (&le;31%), fatigue (3% to 7%), anxiety (3% to 5%), sleep disorder (&le;4%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Xeroderma (&le;2%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Menstrual disease (&le;10%), hypoglycemia (in patients with diabetes) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Oily rectal leakage (4% to 27%), abdominal distress (&le;26%), abdominal pain (&le;26%), flatulence with discharge (2% to 24%), bowel urgency (3% to 22%), steatorrhea (6% to 20%), oily evacuation (2% to 12%), frequent bowel movements (3% to 11%), nausea (4% to 8%), fecal incontinence (2% to 8%), infectious diarrhea (&le;5%), rectal pain (3% to 5%), gingival disease (4%), cholelithiasis (3%), abdominal distension (in patients with diabetes)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Urinary tract infection (6% to 8%), vaginitis (3%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infection: Influenza (&le;40%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Back pain (&le;14%), leg pain (&le;11%), myalgia (&le;4%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Otitis (4%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Upper respiratory tract infection (38%), lower respiratory tract infection (&le;8%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Acute renal failure, anaphylaxis, angioedema, bronchospasm, bullous skin disease, calcium oxalate nephrolithiasis, gastrointestinal hemorrhage (lower), hepatic failure, hepatitis, hypersensitivity, hypersensitivity angiitis, increased serum alkaline phosphatase, increased serum transaminases, pancreatitis, pruritus, renal disease (secondary to increased urinary oxalate excretion), skin rash, urticaria </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203906\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to orlistat or to any component of the formulation; pregnancy; chronic malabsorption syndrome; cholestasis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203892\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cholelithiasis: Substantial weight loss may increase the risk of cholelithiasis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Cases of severe liver injury (some fatal) with hepatocellular necrosis or acute hepatic failure have been reported; liver transplantation has been required in some patients. Patients should be instructed to report any symptoms of hepatic impairment (eg, anorexia, pruritus, jaundice, dark urine, light colored stools, right upper quadrant pain); discontinue therapy immediately and obtain liver function tests if symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Increased urinary oxalate: Increased levels of urinary oxalate following treatment may occur in some patients; cases of oxalate nephrolithiasis and oxalate nephropathy with renal failure have been reported. Monitor renal function in patients at risk for renal impairment; use with caution in patients with a history of hyperoxaluria or calcium oxalate nephrolithiasis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Monitor patients with diabetes closely; weight loss may affect glycemic control. Dosage adjustments of antidiabetic medications may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: When used in adolescents, weight related to growth is accounted for in BMI, therefore, reduction in BMI is a better indicator of weight loss.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Prior to use, other causes for obesity (eg, hypothyroidism) should be ruled out. According to Endocrine Society practice guidelines, weight loss medication should be discontinued and alternative treatment considered if weight loss is &lt;5% of body weight at 3 months or if safety/tolerability issues arise (Apovian, 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dietary guidelines: Patients should be advised to adhere to dietary guidelines; if taken with a diet high in fat (&gt;30% total daily calories from fat), gastrointestinal adverse events may increase. Distribute daily fat intake over 3 main meals. If taken with any 1 meal very high in fat, the possibility of gastrointestinal effects increases. Counsel patients to take a multivitamin supplement that contains fat-soluble vitamins &ge;2 hours before or after orlistat administration to ensure adequate nutrition; orlistat has been shown to reduce the absorption of some fat-soluble vitamins and beta-carotene.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Potential for misuse: The potential exists for misuse in inappropriate patient populations (eg, patients with anorexia nervosa or bulimia) similar to any weight loss agent.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Self-medication (OTC use): Prior to use, patients should contact their healthcare provider if they have ever had kidney stones, gall bladder disease, or pancreatitis. Patients taking medications for diabetes or thyroid disease, seizures, anticoagulants, or other weight-loss products should consult their healthcare provider or pharmacist before use. Patients who have had an organ transplant should not use orlistat. If severe and/or continuous abdominal pain, itching, yellowing of the eyes or skin, dark urine, loss of appetite occurs, or seizures worsen, use should be discontinued and healthcare provider consulted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299795\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203897\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10179&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: Orlistat may decrease the serum concentration of Amiodarone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticonvulsants: Orlistat may decrease the serum concentration of Anticonvulsants. <b> Exceptions: </b>Fosphenytoin; PENTobarbital; Thiopental.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiretroviral Agents: Orlistat may decrease the serum concentration of Antiretroviral Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Orlistat may decrease the serum concentration of CycloSPORINE (Systemic).  Management: Administer orlistat at least 3 hours before or after oral cyclosporine.  Monitor for decreased serum concentrations of oral cyclosporine, even with the recommended dose separation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levothyroxine: Orlistat may decrease the serum concentration of Levothyroxine.  Management: Separate administration of oral levothyroxine and orlistat  by a least 4 hours. Monitor patients closely for signs and symptoms of hypothyroidism.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): Orlistat may decrease the serum concentration of Multivitamins/Fluoride (with ADE). Specifically, orlistat may impair absorption of fat-solube vitamins.  Management: Administer oral fat soluble vitamins (such as vitamins A, D, E, and/or K that are contained in many multivitamin products) at least 2 hours before or after the administration of orlistat.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): Orlistat may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, orlistat may impair the absorption of fat-soluble vitamins.  Management: Administer oral fat soluble vitamins (such as vitamins A, D, E, and/or K that are contained in many multivitamin products) at least 2 hours before or after the administration of orlistat.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): Orlistat may decrease the serum concentration of Multivitamins/Minerals (with AE, No Iron). Specifically, orlistat may impair absorption of fat-solube vitamins.  Management: Administer oral fat soluble vitamins (such as vitamins A, D, E, and/or K that are contained in many multivitamin products) at least 2 hours before or after the administration of orlistat.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paricalcitol: Orlistat may decrease the serum concentration of Paricalcitol.  Management: Monitor clinical response to paricalcitol closely when used with orlistat. When this combination must be used, consider administering paricalcitol at least 1 hour before or 4 to 6 hours after the administration of orlistat<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: Orlistat may decrease the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D Analogs: Orlistat may decrease the serum concentration of Vitamin D Analogs. More specifically, orlistat may impair absorption of Vitamin D Analogs.  Management: Monitor clinical response (including serum calcium) to oral vitamin D analogs closely if used with orlistat.  If this combination must be used, consider giving the vitamin D analog at least 2 hrs before or after orlistat.<b> Exceptions: </b>Calcipotriene; Calcitriol (Topical); Tacalcitol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Orlistat may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamins (Fat Soluble): Orlistat may decrease the serum concentration of Vitamins (Fat Soluble).  Management: Administer oral fat soluble vitamins at least 2 hours before or after the administration of orlistat.  Similar precautions do not apply to parenterally administered fat soluble vitamins.<b> Exceptions: </b>Calcipotriene.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203898\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203909\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Although orlistat is minimally absorbed, weight-loss therapy is not recommended for pregnant women. Obese and overweight women should be encouraged to participate in weight reduction programs prior to attempting pregnancy; weight gain during pregnancy should be determined by their prepregnancy BMI and current guidelines (ADA, 2009; IOM, 2009). Use of orlistat is contraindicated in pregnant women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13761462\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if orlistat is excreted in breast milk. Weight-loss therapy is generally not recommended for lactating women. Weight-loss programs which include physical activity and nutrition components should be discussed at the 6-week postpartum visit (ADA, 2009; IOM, 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203910\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Multivitamin supplements that contain fat-soluble vitamins should be taken once daily at least 2 hours before or after the administration of orlistat (ie, bedtime). Gastrointestinal effects of orlistat may increase if taken with any one meal very high in fat. Distribute daily intake of  carbohydrates, fat (~30% of daily calories), and protein over three main meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7286034\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">BMI; diet (calorie and fat intake); serum glucose in patients with diabetes; thyroid function in patient with thyroid disease; liver function tests in patients exhibiting symptoms of hepatic impairment; renal function in patients at risk for renal impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203891\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">A reversible inhibitor of gastric and pancreatic lipases, thus inhibiting absorption of dietary fats by 30%.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203905\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: 24-48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: 48-72 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Minimal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &gt;99% (lipoproteins and albumin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Metabolized within the gastrointestinal wall; forms inactive metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 1-2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: ~8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (~97%, 83% as unchanged drug); urine (&lt;2%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203908\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Alli Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (90): $52.79</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Xenical Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (90): $703.33</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203911\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alli (CZ, ES, HK, IE, MT, NZ, QA, TW);</li>\n      <li>Aslene (MY);</li>\n      <li>Beacita (ES);</li>\n      <li>Cutarlix (MY);</li>\n      <li>Cuvarix (LK);</li>\n      <li>Digrasil (CO, PE);</li>\n      <li>Ksenikal (UA);</li>\n      <li>Lakshmi (KR);</li>\n      <li>Lesofat (PH);</li>\n      <li>Lipidown (KR);</li>\n      <li>Lysta (LK);</li>\n      <li>Nofat (PH);</li>\n      <li>Obestat (EC);</li>\n      <li>Oliet (KR);</li>\n      <li>Orlifit (LK, VN);</li>\n      <li>Orlis (BD);</li>\n      <li>Orlist (PY);</li>\n      <li>Orlyz (PH);</li>\n      <li>Ornical (BD);</li>\n      <li>Orslim (LK);</li>\n      <li>Redustat (DO, GT, PA, SV);</li>\n      <li>Sidelg (CO, CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Slimfast (BD);</li>\n      <li>Verte (PE);</li>\n      <li>Viplena (EC);</li>\n      <li>Xenical (AE, AR, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BO, BR, BS, BZ, CH, CI, CL, CN, CO, CY, CZ, DE, DK, EC, EE, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HR, HU, ID, IE, IL, IS, IT, JM, KE, KR, KW, LB, LK, LR, LT, LU, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, NZ, PE, PH, PK, PL, PR, PT, PY, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SR, TH, TN, TR, TT, TW, TZ, UG, UY, VE, VN, ZA, ZM, ZW);</li>\n      <li>Xenista (PH);</li>\n      <li>Xenobese (BD);</li>\n      <li>Zero-X (KR);</li>\n      <li>Zerodown (KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alli (orlistat) [prescribing information]. Moon Township, PA: GlaxoSmithKline; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Dietetic Association; American Society of Nutrition, Siega-Riz AM, et al, &quot;Position of the American Dietetic Association and American Society for Nutrition: Obesity, Reproduction, and Pregnancy Outcomes,&quot; <i>J Am Diet Assoc</i>, 2009, 109(5):918-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/orlistat-drug-information/abstract-text/19412993/pubmed\" target=\"_blank\" id=\"19412993\">19412993</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2015;100(2):342-362.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/orlistat-drug-information/abstract-text/25590212 /pubmed\" target=\"_blank\" id=\"25590212 \">25590212 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    August GP, Caprio S, Fennoy I, et al, &ldquo;Prevention and Treatment of Pediatric Obesity: An Endocrine Society Clinical Practice Guideline Based on Expert Opinion,&rdquo; <i>J Clin Endocrinol Metab</i>, 2008, 93(12):4576-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/orlistat-drug-information/abstract-text/18782869/pubmed\" target=\"_blank\" id=\"18782869\">18782869</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, &quot;Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada,&quot; <i>Can J Diabetes</i>, 2013, 35(Suppl 1):1-212.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davidson MH, Hauptman J, DiGirolamo M, et al, &ldquo;Weight Control and Risk Factor Reduction in Obese Subjects Treated for 2 Years With Orlistat: A Randomized Controlled Trial,&rdquo; <i>JAMA</i>, 1999, 281(3):235-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/orlistat-drug-information/abstract-text/9918478/pubmed\" target=\"_blank\" id=\"9918478\">9918478</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heymsfield SB, Segal KR, Hauptman J, et al, &ldquo;Effects of Weight Loss With Orlistat on Glucose Tolerance and Progression to Type 2 Diabetes in Obese Adults,&rdquo; <i>Arch Intern Med</i>, 2000, 160(9):1321-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/orlistat-drug-information/abstract-text/10809036/pubmed\" target=\"_blank\" id=\"10809036\">10809036</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hollander PA, Elbein SC, Hirsch IB, et al, &ldquo;Role of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes. A 1-year Randomized Double-Blind Study,&rdquo; <i>Diabetes Care</i>, 1998, 21(8):1288-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/orlistat-drug-information/abstract-text/9702435/pubmed\" target=\"_blank\" id=\"9702435\">9702435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine) and NRC (National Research Council), &quot;Weight Gain During Pregnancy: Reexamining the Guidelines,&quot; Washington, DC: The National Academies Press, 2009. Available at <a href=\"http://www.nap.edu/\" target=\"_blank\">http://www.nap.edu</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/orlistat-drug-information/abstract-text/20669500/pubmed\" target=\"_blank\" id=\"20669500\">20669500</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McTigue KM, Harris R, Hemphill B, et al, &ldquo;Screening and Interventions for Obesity in Adults: Summary of the Evidence for the U.S. Preventive Services Task Force,&rdquo; <i>Ann Intern Med</i>, 2003, 139(11):933-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/orlistat-drug-information/abstract-text/14644897/pubmed\" target=\"_blank\" id=\"14644897\">14644897</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Heart, Lung, and Blood Institute Obesity Education Initiative, &ldquo;Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. The Evidence Report,&rdquo; <i>NIH Publication </i>No. 98-4083. Bethesda, MD: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute, 1998.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Snow V, Barry P, Fitterman N, et al, &ldquo;Pharmacologic and Surgical Management of Obesity in Primary Care: A Clinical Practice Guideline From the American College of Physicians,&rdquo; <i>Ann Intern Med</i>, 2005, 142(7):525-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/orlistat-drug-information/abstract-text/15809464/pubmed\" target=\"_blank\" id=\"15809464\">15809464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Torgenson JS, Pauptman J, Boldrin MN, et al, &ldquo;XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: A Randomized Study of Orlistat as an Adjunct to Lifestyle Changes for the Prevention of Type 2 Diabetes in Obese Patients,&rdquo; <i>Diabetes Care</i>, 2004, 27(1):155-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/orlistat-drug-information/abstract-text/14693982/pubmed\" target=\"_blank\" id=\"14693982\">14693982</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weir MA, Beyea MM, Gomes T, et al, &quot;Orlistat and Acute Kidney Injury: An Analysis of 953 Patients,&quot; <i>Arch Intern Med</i>, 2011, 171(7):703-4.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Xenical (orlistat) [prescribing information]. Montgomery, AL: H2-Pharma LLC; January 2018.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10179 Version 126.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F203918\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F203919\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F203947\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F203922\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F203935\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F203923\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F20548142\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F20548143\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F203901\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F203888\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F7286032\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F203902\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F2702460\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F203895\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F203906\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F203892\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299795\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F203897\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F203898\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F203909\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13761462\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F203910\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F7286034\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F203891\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F203905\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F203908\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F203911\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10179|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=orlistat-patient-drug-information\" class=\"drug drug_patient\">Orlistat: Patient drug information</a></li></ul></div></div>","javascript":null}